Autolus engineers a $100M-plus IPO for itself as it blueprints a new generation of better, safer cell therapies
The London-based T cell engineers at Autolus are steering the company to a $100 million-plus IPO, hoping to bank on a so far insatiable …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
